

**Amendments to the Claims**

Please cancel Claims 6 and 10-45. Please amend Claims 1 and 7. Please add new Claim 46. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A pharmaceutical composition comprising a vaccine and an immunostimulatory ~~therapeutically effective~~ amount of a polypeptide, wherein said polypeptide comprises an HMGB B box or a functional variant thereof and does not comprise an HMGB A box, ~~and wherein said polypeptide increases an immune response in an individual administered said pharmaceutical composition.~~
2. (Original) The pharmaceutical composition of Claim 1, wherein said HMGB B box is mammalian.
3. (Original) The pharmaceutical composition of Claim 2, wherein said HMGB B box is human.
4. (Original) The pharmaceutical composition of Claim 3, wherein said polypeptide comprises an HMGB1 B box polypeptide.
5. (Original) The pharmaceutical composition of Claim 4, wherein said polypeptide consists of an HMGB1 B box polypeptide.
6. (Canceled)
7. (Currently Amended) The pharmaceutical composition of ~~Claim 6~~ Claim 1, further comprising an adjuvant.
8. (Original) The pharmaceutical composition of Claim 7, wherein said adjuvant is selected from the group consisting of one or more immunostimulatory oligonucleotides, an imidazoquinoline, monophosphoryl lipid A, and detoxified lipopolysaccharide.

9. (Original) The pharmaceutical composition of Claim 8, wherein said immunostimulatory oligonucleotides comprise unmethylated CpG sequences.

10-45. (Canceled)

46. (New) The pharmaceutical composition of Claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 5, 16, 20, 23 and 45.